Azienda USL IRCCS Di Reggio Emilia
- Address
- Via Donatori Di Sangue 1, 42016 Guastalla, Italy
Azienda USL IRCCS Di Reggio Emilia - Breast Cancer Research Center
Azienda USL IRCCS Di Reggio Emilia is an advanced clinical research institution specializing in oncology, with particular expertise in breast cancer treatment and precision medicine approaches. The center is actively engaged in international multicenter trials investigating innovative therapeutic strategies for hormone receptor-positive breast cancers.
- ER+/HER2- early breast cancer treatment optimization
- Circulating tumor DNA (ctDNA) monitoring and relapse detection
- Novel endocrine therapy approaches for metastasis prevention
The research center focuses on cutting-edge studies evaluating targeted endocrine therapies such as elacestrant, aiming to improve distant metastasis-free survival in patients with detectable ctDNA relapse. Through participation in phase III randomized clinical trials, the institution contributes to advancing personalized treatment strategies that combine molecular monitoring with innovative pharmaceutical interventions to prevent disease progression in early-stage breast cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda USL IRCCS Di Reggio Emilia
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| EORTC 2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) | Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 1 | Unknown | 2024-02-23 | 2024-02-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.